Search Within

Matthew J Matasar

  1. "Bone Marrow Transplant"
  2. "Population Sciences Research Program"
Formats
  1. Meeting Abstract (20)
  2. Journal Article (9)
Groups
  1. Bone Marrow Transplant (29)
  2. Center for Hematologic Malignancies (29)
  3. Department of Medicine (29)
  4. Hematologic Malignancies, Division of (29)
  5. Lymphoma (29)
  6. Population Sciences Research Program (29)

More Groups

People
  1. Andrew Zelenetz (27)
  2. Steven Horwitz (27)
  3. Alison Moskowitz (26)
  4. Ariela Noy (26)
  5. David Straus (24)
  6. Paul Hamlin (24)

More People

Years
  1. 2022 (1)
  2. 2021 (3)
  3. 2020 (2)
  4. 2019 (5)
  5. 2017 (7)
  6. 2016 (4)

More Years

Publications
  1. Blood (18)
  2. Hematological Oncology (3)
  3. Journal of Clinical Oncology (3)
  4. Blood Advances (1)
  5. Clinical Lymphoma, Myeloma and Leukemia (1)
  6. Haematologica (1)

More Publications

Publishers
  1. American Society of Hematology (19)
  2. American Society of Clinical Oncology (3)
  3. Wiley Blackwell (3)
  4. Elsevier Inc. (1)
  5. Elsevier Science, Inc. (1)
  6. Ferrata Storti Foundation (1)

More Publishers

Results (29)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Impact of choice of platinum-based salvage therapy on CNS relapse in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Buege, M. J.; Dao, P.; Dematteo, R. G.; LeVoir, A.; Pak, T.; Batlevi, C. L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Khimani, F.; Shustov, A. R.; Shadman, M.; Ruan, J.; Moskowitz, A. J.; Straus, D. J.; Kumar, A.; Sauter, C. S.; Zelenetz, A. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies
    Journal Article

    Sermer, D.; Batlevi, C.; Lia Palomba, M.; Shah, G.; Lin, R. J.; Perales, M. A.; Scordo, M.; Dahi, P.; Pennisi, M.; Afuye, A.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Retrospective analysis of gemcitabine and oxaliplatin (GemOx)-based treatment in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Meeting Abstract

    Schade, J. R.; Kim, C.; Drill, E.; Qiu, A.; Batlevi, C. L.; Caron, P.; Colbourn, D. S.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term follow-up confirms durability of single-agent brentuximab vedotin as pre-transplant salvage for classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Schoder, H.; Lee, J.; Davey, T.; Hancock, H.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; Noy, A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase II, multicenter study of high dose chemotherapy with autologous stem cell transplant followed by maintenance therapy with romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Shustov, A. R.; Khimani, F.; Shadman, M.; Cassaday, R. D.; Ruan, J.; Moskowitz, A. J.; Zelenetz, A. D.; Noy, A.; Straus, D. J.; more...
    Blood (2019)

    Fulltext@MSK | Save